Adam Elisha, D.O. recently completed his residency in internal medicine at Providence Sacred Heart Medical Center in Spokane, WA. Dr. Elisha subsequently recently received his independent practitioner license for the state of Washington.
Dr. Elisha attended the University of Toronto in Toronto, Ontario for his undergraduate education. Dr. Elisha majored in neuroscience and political science. He was awarded an Honors Bachelor of Science (H.B.Sc) degree as well as Dean's List distinction.
Before attending medical school, Dr. Elisha spent two years teaching physics to underserved teenagers in downtown Toronto, Ontario.Dr. Elisha attended Midwestern University (Arizona College of Osteopathic Medicine) for his medical education. Upon completing medical school, Dr. Elisha continued his medical training as an internal medicine resident in Spokane, Washington at Providence Sacred Heart Medical Center, a University of Washington affiliate program.Dr. Elisha is passionate about preventative health care and assisting his patients achieve both short and long term optimization of their health and well-being. Dr. Adam Elisha is a member of the American College of Physicians (ACP) and the American College of Rheumatology (ACR). His current academic interests include hospital medicine and spondyloarthropy research, particularly novel therapeutics.
Further, Dr. Elisha has a strong interest in addiction medicine and harm reduction approaches to combat the growing opioid epidemic in the United States. He recently completed additional training and received certification from the Substance Abuse and Mental Health Services Administration (SAMHSA) and is now authorized to prescribe bupenorphine for medication assisted treatment (MAT) for those suffering from opioid addiction.
Dr. Elisha will be continuing his training in rheumatology as a fellow at the Univsersity of Pittsburgh Medical Center (UPMC) in September 2017.
Dr. Elisha looks forward to continuing to clinically train and complete rheumatologic research, again with a focus on novel therapeutic agents in the management of spondyloarthropies.